# PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

> **NCT04115410** · — · UNKNOWN · sponsor: **Sungkyunkwan University** · enrollment: 4724 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Immune-Related Adverse Events

## Interventions

- **DRUG:** PD-1 inhibitor
- **DRUG:** Chemotherapy Drugs, Cancer

## Key facts

- **NCT ID:** NCT04115410
- **Lead sponsor:** Sungkyunkwan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-12-31
- **Target enrollment:** 4724 (ESTIMATED)
- **Last updated:** 2020-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04115410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04115410, "PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04115410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*